NCT02546583View on ClinicalTrials.gov

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 23, 2020

Study Completion Date

January 23, 2020

Conditions
Heart Failure
Interventions
DRUG

Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)

An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).

DRUG

IV Chlorothiazide

Trial Locations (1)

Unknown

Yale University, New Haven

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Yale University

OTHER

NCT02546583 - Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure | Biotech Hunter | Biotech Hunter